Global Classical Swine Fever Vaccines Market - 2022-2029

Market Overview

Classical Swine Fever Vaccines Market was valued at USD XX million in 2021. It is forecasted to reach USD XX million by 2029, growing at a CAGR of 7.5 % during the forecast period (2022-2029).

Classical swine fever is a contagious and economically significant viral disease of pigs. The severity of the illness varies with the strain of the virus, the pig's age, and the herd's immune status. Classical swine fever is related to the virus of bovine virus diarrhea (BVD) and sheep's border disease (BD). Suvaxyn CSF Marker is a veterinary vaccine that protects pigs against outbreaks of classical swine fever. It also protects breeding sows to reduce infection of their unborn piglets by classical swine fever virus. This vaccine contains live bovine viral diarrhea virus (BVDV), which has been modified to replace the envelope (E2) gene of BVDV with the corresponding gene of CSFV. The rising prevalence of awareness regarding the classical swine fever vaccines and the increasing consumption of pork meat are some factors that are expected to propel market growth. Moreover, the introduction of new veterinary vaccines by animal health companies is further supporting the growth of the market across the globe.

Market Dynamics: The introduction of a new veterinary vaccine will continue supporting the market's growth during the forecast period.

Veterinary vaccines improve companion animals' health and prevent animal-to-human transmission of diseases and infections from domestic animals and wildlife. It has led to the development of new veterinary vaccines by animal health companies. One of the major factors augmenting the market's growth includes the number of new veterinary vaccines introduced by veterinary vaccine manufacturers. In May 2020, Indian Immunologicals Limited (IIL) launched the Classical Swine Fever (CSF) vaccine under the brand name 'Raksha Class .'This vaccine was developed in collaboration with the Indian Veterinary Research Institute (IVRI), Bareilly.

Also, Continuous R&D in the field of swine fever is driving the growth of the global classical swine fever market. Classical swine fever (CSF), also termed hog cholera, is an infectious viral disease of pigs, including wild boar. The connective virus is a member of the Flaviviridae's genus Pestivirus family and is intimately connected to bovine viral diarrhea and border disease. It leads to the high fatality of pigs across several countries, including India. The country has been using the UK-developed classical swine fever vaccine since 1964; however, the country is developing a locally manufactured classical swine fever vaccine for the increasing pig population in India.

Moreover, increasing awareness of the vaccination of swineherds is driving the growth of the global market. Vaccination is a necessary tool for controlling diseases in swine herds. The swine vaccine is designed to reduce the number of susceptible animals, clinical diseases, and pathogen spread. The swine vaccine prevents swine from contagious diseases, in which active and passive immunity are methods to protect against disease. According to the Swine Health Information Center (SWIC), Porcine teschovirus (PTV) is a non-enveloped RNA virus in the genusTeschovirus and the family Picornaviridae. There are about 13 known PTV serotypes in which the PTV-1 is linked with teschovirus encephalomyelitis. PTV-2, PTV -3, and PTV -5 are linked with Talfan disease. The PTV infection in swine may be subclinical.

However, stringent regulatory policies are restraining the growth of the global classical swine fever vaccine market. Various regulations and policies are required to approve and authorize animal vaccination. Each country has its regulatory organizations that set the standards and protocols for animal vaccination. For instance, the Center for Veterinary Biologics (CVB) in the Animal and Plant Health Inspection Service (APHIS), a USDA branch, regulates vaccine production and marketing in the US. The animal health companies must have both a product license and an establishment license granted by the CVB rules. These licenses are given under some conditions such as inspected facilities and appropriate. The CVB requires all products to undergo an approval process to ensure compliance with the four characteristics outlined in the Virus-Serum-Toxin Act of 1913, including purity, potency, safety, and efficacy.

Market Segmentation: Government tender segment accounted for the highest share in global classical swine fever vaccines market.

The government tender segment held a major share in the classical swine fever vaccines market in the forecast year. The government has a huge focus on containing the spread of classical swine fever, owing to which the government tender is scheduled for the sales of the classical swine fever vaccine. Moreover, the more effective vaccine in government organizations or private organizations under the government's supervision is further expected to contribute to the segment's growth during the forecast period.

The classical swine fever vaccine market has been classified into tissue culture origin and cell line origin based on the type. The tissue culture origin segment accounted for a significant market share in the global classical swine fever vaccine market. Tissue culture origin dominated the classical swine fever vaccines market in the forecast period. Cell culture is widely used in the US biopharmaceutical industries for vaccine production, drug development, and tissue culture. Tissue culture has a huge significance in the classical swine fever vaccine; therefore, considerable growth can be projected in the segment during the forecast period.

Geographical Penetration: North America is the dominating region during the forecast period.

North America dominated the global classical swine fever vaccines market and is expected to retain its position during the forecast period. The US contributed the highest market share in the North American classical swine fever vaccines market in the forecast period. The well-developed healthcare infrastructure and the huge spending on R&D for the development of novel vaccines for a range of diseases are some factors supporting the growth of the classical swine fever vaccines market in the region.

Europe holds a second dominant position in the global classical swine fever vaccines market. The high consumption of pork meat is one of the major factors that drive the market growth in the region. Spain comprises a significant share of the pork industry in Europe. Pork production is mainly accounted for in western parts of the country due to substantial pork breeding farms. Growing marginalization in the pork industry is also one of the major factors contributing to pork husbandry's concentrated market. Spain accounted for 24% of Europe's pigs.

The Asia Pacific is estimated to grow at a considerable growth rate in the classical swine fever vaccines market during the forecast period. This growth can be accredited to the rising R&D for an effective vaccine. For instance, in February 2020, Indian Scientists developed a new vaccine in India to control classical swine fever. This vaccine helps in producing an effective cast alternative to currently used vaccines for preventing the deadly fever in pigs that contribute to 10 % of the country's total meat production.

Competitive Landscape:

The classical swine fever vaccine market is highly competitive. The key classical swine fever vaccine players contributing to the global market's growth include Panav Biotech, Boehringer Ingelheim International GmbH, Ceva, Bioveta, a.s., Indian Immunologicals Limited, and Qilu Animal Health Products Co., Ltd. among others. The major players are adopting new product launches and expansion strategies for global growth in the classical swine fever vaccines market. Some key players launched a new product in the market to expand their product portfolio. In June 2020, Boehringer Ingelheim announced the China-developed classical swine fever vaccine and obtained a "New veterinary drug registration certificate" from the Ministry of Agriculture and Rural Affairs of China. It is regarded as the first classical swine fever live vaccine jointly developed by a multinational company and Chinese research institutes. Some key players follow merger and acquisition strategies to expand their business. For instance, in December 2021, Boehringer Ingelheim to Acquired Labor Dr. Merk & Kollegen to Strengthen its Next Generation Cancer Immunology Program. This acquisition helped to expand and accelerate its comprehensive program for the development of ATMP-based immuno-oncology therapies, including the Vesicular Stomatitis Virus (VSV) with modified glycoprotein (GP) platform and cancer vaccine platforms.

COVID-19 Impact: Negative impact on the global classical swine fever vaccines market.

The outbreak of COVID-19 has certainly impacted the global classical swine fever vaccines market, as the lockdown has compelled the supply of classical swine fever vaccines across the globe. The researchers' shift in focus toward developing the COVID-19 vaccine has hampered the R&D in the classical swine fever vaccines. Therefore, the classical swine fever vaccine market is expected to foresee a considerable decline in 2020.